Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

Plain-language guide to NCT07040592: phase 2 interventional trial of Semaglutide, 30 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT07040592
Phase: phase 2
Status: recruiting participants
Start: 2026-01-15
Completion (planned or actual): 2027-06-30
Participants: 30 (estimated)
Design: na, open label (everyone knows who gets what), treatment
Conditions studied: Alcohol Use Disorder (AUD); HIV
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

In this phase 2 trial, researchers set out to test Semaglutide.

It had 1 arm (groups): Semaglutide (experimental).

Participants will receive a prescription for semaglutide.

The registry classes the interventions as drug.

More on the Plan

In addition, participants will be offered semaglutide in the third pilot study.

Participants will be interviewed with regards to their perspectives on feasibility and acceptability.

Several assessments including interviews and laboratory testing will be done at study visits.

Who Took Part

30 planned participants were the target.

It was open to people of any sex aged from 18 years up to 99 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Diagnosed with HIV. Receive care at the Atlanta VA Healthcare System. Age 18 or over. Prescribed \>=5 medications. Have cell phone or reliable contact number.

The full record lists 8 inclusion and 13 exclusion criteria; among the exclusions: self-report or laboratory test confirming pregnancy, nursing, or trying to conceive; untreated moderate to severe opioid use disorder; residence out of state.

How the Study Was Run

The set-up was single-group and open-label.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2026-01-15 with completion listed for 2027-06-30.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Proportion of participants who complete enrollment and duration of sessions (time frame: 12 weeks). Number of sessions completed (time frame: 12 weeks). Adherence to Medication (time frame: 12 weeks).

What This Means in Plain Language

Put simply, this is a phase 2 trial of Semaglutide in 30 people.

Its size is small, so on its own it can only give an early look.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.

Our Notes on the Compound

Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).

Semaglutide in the library

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.